Gavilimomab
From Wikipedia, the free encyclopedia
|
Gavilimomab
|
|
|
|
|
| Source | Mouse |
| Target | CD147 |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Gavilimomab is a mouse monoclonal antibody (also known as ABX-CBL) is an immunosuppresive drug. It binds to antigen CD147.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Abatacept, Abetimus, Adalimumab, Afelimomab, Anakinra, Alefacept, Antilymphocyte immunoglobulin (horse), Antithymocyte immunoglobulin (rabbit), Aselizumab, Atlizumab, Atorolimumab, Azathioprine, Basiliximab, Belatacept, Belimumab, Bertilimumab, Cedelizumab, Ciclosporin, Citilimumab, Clenoliximab, Daclizumab, Difirolimus, Dofosirolimus, Dorlimomab aritox, Eculizumab, Efalizumab, Elsilimomab, Enlimomab, Enlimomab pegol, Erlizumab, Etanercept, Everolimus, Faralimomab, Fontolizumab, Galiximab, Gavilimomab, Gifosirolimus, Golimumab, Gomiliximab, Gusperimus, Infliximab, Inolimomab, Ipilimumab, Keliximab, Leflunomide, Lerdelimumab, Lumiliximab, Maslimomab, Mepolizumab, Metelimumab, Methotrexate, Morolimumab, Muromonab-CD3, Mycophenolic acid, Natalizumab, Nerelimomab, Ocrelizumab, Odulimomab, Omalizumab, Pascolizumab, Pexelizumab, Pimecrolimus, Reslizumab, Rovelizumab, Ruplizumab, Safosirolimus, Siplizumab, Sirolimus, Tacrolimus, Talizumab, Telimomab aritox, Teneliximab, Thalidomide, Ticilimumab, Tilolizumab, Tocilizumab, Toralizumab, Torolimus, Vapaliximab, Vepalimomab, Visilizumab, Zanolimumab, Ziralimumab, Zolimomab aritox
Abagovomab, Afelimomab, Altumomab, Anatumomab mafenatox, Arcitumomab, Bectumomab, Besilesomab, Biciromab brallobarbital, Capromab, Detumomab, Dorlimomab aritox, Edobacomab, Edrecolomab, Elsilimomab, Enlimomab, Enlimomab pegol, Epitumomab, Epitumomab cituxetan, Fanolesomab, Faralimomab, Gavilimomab, Ibritumomab tiuxetan, Igovomab, Imciromab, Inolimomab, Lemalesomab, Maslimomab, Minretumomab, Mitumomab, Nacolomab tafenatox, Nerelimomab, Nofetumomab merpentan, Odulimomab, Oregovomab, Pemtumomab, Pintumomab, Satumomab, Sulesomab, Taplitumomab paptox, Telimomab aritox, Tositumomab, Vepalimomab, Zolimomab aritox
